BROOKLYN, NY, UNITED STATES, January 31, 2018 /EINPresswire.com/ — The Global Oncology market size is expected to exceed USD 190 billion by 2022. The Immuno-Oncology market was valued at USD 6 billion representing 7% of the global Oncology market in 2016 but is expected to grow at a impressive CAGR of ~30% during the forecast period from 2016-2022 as reported by Polaris Market Research.
The immune-checkpoint blockade, is the revolutionizing treatment options in almost all oncology disease areas which has witnessed the rapid uptake in the growing Oncology market. These therapies are largely dependent on the global immune system of each individual patient, and not necessarily dependent only on the tumor biology which makes it the truly personalized medicine.
As of December 2017, there are 6 Immuno-Oncology therapies which have been launched in the market, with the Opdivo and Keytruda being the highest sales generating drugs. There are dozens of targets being tested across hundreds of clinical trials ongoing for Cancer therapy area as a monotherapy and as combination trials.
Polaris Market Research estimates that with the expected launch of the potential Immuno-Oncology, the market is expected grow at a higher rate. The Unites States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is subjected to the growth of the two immunotherapies ie Keytruda (Merck) and Opdivo (Bristol Myers Squibb), expansion of these therapies in other cancers and rapid uptake of overall immunotherapies.
On the flip side, with the approval of the immunotherapies, the complexity of cancer treatment in patients as a personalized medicine has also increased. These therapies are thought to be largely dependent on the global immune system of each individual patient, and not necessarily dependent only on the tumor biology. Even the target-specific molecular characteristics of a tumor are only present in a small proportion of patients which are to be cured by immunotherapies. Therefore, new technologies are needed that can help predict which patients will benefit from immunotherapy.
Polaris Market Research has provided the forecasts of the Global Immuno-Oncology Therapies Market from 2016-2022.
The major segments which has been investigated in the global market from 2016-2022 are:
1. Market Analysis by Marketed Immuno-Oncology Therapies
2. Market Analysis by Companies
3. Market Analysis by Indications
The Marketed Therapies undertaken in forecast from 2016-2022 are:
1. Yervoy (Bristol Myers Squibb)
2. Keytruda (Merck)
3. Opdivo (Bristol Myers Squibb)
4. Tecentriq (Roche)
5. Bavencio (Merck/Pfizer)
6. Imfinzi (AstraZeneca)
7. Epacadostat (Incyte Pharmaceuticals)
8. Tremelimumab (AstraZeneca)
The Major Indications in Immuno-Oncology Therapies are:
2. Lung Cancer
3. Small Cell Lung Cancer (SCLC)
4. Non-Small Cell Lung Cancer (NSCLC)
5. Head & Neck Squamous Cell Carcinoma (HNSCC)
6. Renal Cell Cancer
7. Bladder Cancer
Leading Companies investigated in the Report are
1. Bristol Myers Squib (BMS)
2. Merck (MRK)
3. AstraZeneca (AZ)
4. Bristol Myers Squib (BMS)
5. Roche Holding AG (RHHBY)
6. Pfizer (PFE)
7. Incyte (INCY)
8. Other Companies
Browse other reports by Polaris Market Research:
Polaris Market Research & Consulting
email us here
Source: EIN Presswire